Efavirenz

Generic Name
Efavirenz
Brand Names
Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
Drug Type
Small Molecule
Chemical Formula
C14H9ClF3NO2
CAS Number
154598-52-4
Unique Ingredient Identifier
JE6H2O27P8
Background

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication

For use in combination treatment of HIV infection (AIDS)

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

First Posted Date
2009-10-09
Last Posted Date
2019-05-14
Lead Sponsor
University of California, San Francisco
Target Recruit Count
389
Registration Number
NCT00993031
Locations
🇺🇬

Tororo District Hospital, Tororo, Uganda

Efavirenz in Treating Patients With Metastatic Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: efavirenz
First Posted Date
2009-08-24
Last Posted Date
2022-05-16
Lead Sponsor
Institut Bergonié
Target Recruit Count
61
Registration Number
NCT00964002
Locations
🇫🇷

Institut Bergonie, Bordeaux, France

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2
Conditions
Pancreatic Cancer
First Posted Date
2009-08-24
Last Posted Date
2010-04-07
Lead Sponsor
Institut Bergonié
Target Recruit Count
72
Registration Number
NCT00964171
Locations
🇫🇷

Institut Bergonie, Bordeaux, France

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

First Posted Date
2009-08-03
Last Posted Date
2018-01-16
Lead Sponsor
ViiV Healthcare
Target Recruit Count
208
Registration Number
NCT00951015
Locations
🇪🇸

GSK Investigational Site, Madrid, Spain

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Phase 2
Completed
Conditions
HIV
HIV Infections
Interventions
Drug: Stribild
Drug: Atripla
First Posted Date
2009-03-26
Last Posted Date
2014-06-04
Lead Sponsor
Gilead Sciences
Target Recruit Count
71
Registration Number
NCT00869557
Locations
🇺🇸

Northstar Medical Center, Chicago, Illinois, United States

🇺🇸

Southampton Healthcare, Inc., St. Louis, Missouri, United States

🇺🇸

Gordon E. Crofoot, MD, PA, Houston, Texas, United States

and more 27 locations

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Phase 2
Completed
Conditions
HIV Infections
Tuberculosis
Interventions
Drug: efavirenz
Drug: raltegravir
First Posted Date
2009-01-14
Last Posted Date
2013-07-17
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
155
Registration Number
NCT00822315
Locations
🇧🇷

Ipec/Fiocruz, Rio de Janeiro, Brazil

🇧🇷

Hospitral Universitario Pr Edgar Santos, Salvador da Bahia, Brazil

🇫🇷

Hôpital Saint-Louis, Paris, France

and more 6 locations

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz

Not Applicable
Completed
Conditions
Sleep Disorders
Interventions
Drug: efavirenz
Drug: etravirine
First Posted Date
2008-11-18
Last Posted Date
2011-09-12
Lead Sponsor
University Hospital, Geneva
Target Recruit Count
50
Registration Number
NCT00792584
Locations
🇨🇭

Geneva Hospital, Geneva, Switzerland

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

Phase 3
Completed
Conditions
HIV
Interventions
Drug: Etravirine
Drug: Efavirenz
First Posted Date
2008-11-17
Last Posted Date
2009-11-18
Lead Sponsor
St Stephens Aids Trust
Target Recruit Count
24
Registration Number
NCT00792324
Locations
🇬🇧

Chelsea and Westminster Hospital, London, United Kingdom

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

First Posted Date
2008-10-20
Last Posted Date
2023-05-26
Lead Sponsor
Rush University Medical Center
Target Recruit Count
15
Registration Number
NCT00775606
Locations
🇺🇸

University of Illinois Medical Center, Chicago, Illinois, United States

🇺🇸

University of Chicago Hospital, Chicago, Illinois, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: Kaletra + Isentress
Drug: Atripla
First Posted Date
2008-09-16
Last Posted Date
2020-07-22
Lead Sponsor
University of California, San Diego
Target Recruit Count
51
Registration Number
NCT00752856
Locations
🇺🇸

Living Hope Clinical Foundation, Long Beach, California, United States

🇺🇸

Desert AIDS Project, Palm Springs, California, United States

🇺🇸

Univerisity California Irvine, Orange, California, United States

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy